2021
Commentary: Treatment-resistant Depression: Considerations Related to ECT and Ketamine
Garakani A. Commentary: Treatment-resistant Depression: Considerations Related to ECT and Ketamine. Journal Of Psychiatric Practice 2021, 27: 496-497. PMID: 34768276, DOI: 10.1097/pra.0000000000000593.Commentaries, Editorials and LettersMeSH KeywordsAdultAgedDepressionDepressive Disorder, MajorDepressive Disorder, Treatment-ResistantElectroconvulsive TherapyFemaleHumansKetamineMaleMiddle AgedConceptsTreatment-resistant depressionElectroconvulsive therapyLiver transplantationChronic treatment-resistant depressionUse of ECTMaintenance electroconvulsive therapyMajor depressive episodeBitemporal treatmentsIntranasal formsIntranasal ketaminePartial responsePrescribed antipsychoticsAdjunctive treatmentAntirejection medicationsChronic migraineMigraine medicationsECT treatmentComorbid migraineDepressive episodePsychotic featuresOrgan transplantationKetamine abuseBrain stimulationClinical considerationsPatientsSelective Serotonin Reuptake Inhibitors: How Long Is Long Enough?
Thom RP, Alexander JL, Baron D, Garakani A, Gross L, Pine JH, Radhakrishnan R, Slaby A, Sumner CR. Selective Serotonin Reuptake Inhibitors: How Long Is Long Enough? Journal Of Psychiatric Practice 2021, 27: 361-371. PMID: 34529602, DOI: 10.1097/pra.0000000000000578.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAdolescentAgedAnxiety DisordersDepressive Disorder, MajorHumansSelective Serotonin Reuptake InhibitorsConceptsSelective serotonin reuptake inhibitorsLong-term SSRI useSSRI useEase of titrationFirst-line medicationSerotonin reuptake inhibitorsRisk-benefit ratioMajor depressive disorderGeneral health risksShort-term useClinical practice considerationsDiscontinuation syndromeReuptake inhibitorsSafety profileDepressive disorderPatientsPsychiatric conditionsRelapse preventionMedicationsPossible adverse consequencesSpecial populationsAnxiety disordersTolerabilityPrescribersAdverse consequences
2012
Cerebrospinal fluid levels of glutamate and corticotropin releasing hormone in major depression before and after treatment
Garakani A, Martinez JM, Yehuda R, Gorman JM. Cerebrospinal fluid levels of glutamate and corticotropin releasing hormone in major depression before and after treatment. Journal Of Affective Disorders 2012, 146: 262-265. PMID: 22840611, DOI: 10.1016/j.jad.2012.06.037.Peer-Reviewed Original Research
2011
PROINFLAMMATORY AND “RESILIENCY” PROTEINS IN THE CSF OF PATIENTS WITH MAJOR DEPRESSION
Martinez JM, Garakani A, Yehuda R, Gorman JM. PROINFLAMMATORY AND “RESILIENCY” PROTEINS IN THE CSF OF PATIENTS WITH MAJOR DEPRESSION. Depression And Anxiety 2011, 29: 32-38. PMID: 21898706, DOI: 10.1002/da.20876.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntidepressive Agents, Second-GenerationBrain-Derived Neurotrophic FactorCyclohexanolsDepressive Disorder, MajorFemaleHumansInflammationInflammation MediatorsInterleukin-1Interleukin-6MaleMiddle AgedNeuropeptide YSeverity of Illness IndexTumor Necrosis Factor-alphaUp-RegulationVenlafaxine HydrochlorideConceptsInflammatory cytokinesDepressed patientsHealthy controlsMajor depressionCSF cytokine levelsCSF of patientsCerebrospinal fluid levelsLumbar puncture procedureNormal comparison groupInflammatory hypothesisNPY concentrationsNPY levelsCytokine levelsIL-6Lumbar punctureClinical severityTreatment protocolIL-1CSF samplesPatientsNeuroprotective peptideFluid levelsSuicidal ideationPuncture procedureSmall sample size
2008
A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder
Garakani A, Martinez JM, Marcus S, Weaver J, Rickels K, Fava M, Hirschowitz J. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. International Clinical Psychopharmacology 2008, 23: 269-275. PMID: 18703936, DOI: 10.1097/yic.0b013e328301a74c.Peer-Reviewed Original ResearchConceptsMontgomery-Asberg Depression Rating Scale scoreMajor depressive disorderDepression Rating Scale scoresHamilton Anxiety ScaleRating Scale scoresPlacebo groupDepressive disorderScale scoreCGI improvement scoreCombination of quetiapinePlacebo-controlled trialClinical global improvementWeeks of treatmentOnset of actionMixed effects linear regressionQuetiapine augmentationAnxiety ScaleFluoxetine groupFluoxetine treatmentCGI scoresImproved sleepMixed effects regressionInsomnia scoresQuetiapineFluoxetine